scholarly journals Contemporary Molecular Analyses of Malignant Tumors for Precision Treatment and the Implication in Oral Squamous Cell Carcinoma

2021 ◽  
Vol 12 (1) ◽  
pp. 12
Author(s):  
Julia Yu Fong Chang ◽  
Chih-Huang Tseng ◽  
Pei Hsuan Lu ◽  
Yi-Ping Wang

New molecular tests and methods, in addition to morphology-based diagnosis, are widely used as a new standard of care in many tumors. “One-size-fits-all medicine” is now shifting to precision medicine. This review is intended to discuss the key steps toward to development of precision medicine and its implication in oral squamous cell carcinoma. The challenges and opportunities of precision medicine in oral cancer will be sequentially discussed based on the four steps of precision medicine: identification/detection, diagnosis, treatment and monitoring.

2022 ◽  
Vol 2 ◽  
Author(s):  
Rasheed Omobolaji Alabi ◽  
Alhadi Almangush ◽  
Mohammed Elmusrati ◽  
Antti A. Mäkitie

Oral squamous cell carcinoma (OSCC) is one of the most prevalent cancers worldwide and its incidence is on the rise in many populations. The high incidence rate, late diagnosis, and improper treatment planning still form a significant concern. Diagnosis at an early-stage is important for better prognosis, treatment, and survival. Despite the recent improvement in the understanding of the molecular mechanisms, late diagnosis and approach toward precision medicine for OSCC patients remain a challenge. To enhance precision medicine, deep machine learning technique has been touted to enhance early detection, and consequently to reduce cancer-specific mortality and morbidity. This technique has been reported to have made a significant progress in data extraction and analysis of vital information in medical imaging in recent years. Therefore, it has the potential to assist in the early-stage detection of oral squamous cell carcinoma. Furthermore, automated image analysis can assist pathologists and clinicians to make an informed decision regarding cancer patients. This article discusses the technical knowledge and algorithms of deep learning for OSCC. It examines the application of deep learning technology in cancer detection, image classification, segmentation and synthesis, and treatment planning. Finally, we discuss how this technique can assist in precision medicine and the future perspective of deep learning technology in oral squamous cell carcinoma.


2020 ◽  
Vol 2 (2) ◽  
Author(s):  
Yetao Wang ◽  
Suying Qian ◽  
Kesang Li

Targeted immune checkpoint-based immunotherapy has achieved remarkable success in the treatment of malignant tumors. Immune checkpoint inhibitor-programmed cell death protein 1 (PD-1) antibody opens a new era of immunotherapy for platinum-refractory recurrent/metastatic oral squamous cell carcinoma (OSCC). The overall survival of patients treated with immunological checkpoint inhibitors was significantly prolonged, and the overall incidence of grade 3-4 drug-related adverse events (AEs) occurred was lower. This article briefly describes the development of PD-1 inhibitors in the treatment of OSCC. The purpose of this review is to briefly highlight the clinical development of PD-1 inhibitors in OSCC therapy to date.


2020 ◽  
Vol 12 (7) ◽  
pp. 946-952
Author(s):  
Fengping Mou ◽  
Li Xiao ◽  
Yuanqin Xu

This study aims to investigate the therapeutic effect of a paclitaxel-loaded nano-drug (PTX-mPEGPLA) on oral squamous cell carcinoma (OSCC). PTX-mPEG-PLA nanoparticle (NP) was prepared by loading paclitaxel into the mPEG-PLA nanoparticle and purified by a thin-film hydration method. C57BL/6 mice were used to establish a murine OSCC model. The mice were treated with saline control (G1), paclitaxel (G2), or PTX-mPEG-PLA NPs (G3). After 4 weeks of differential treatment, the saliva of mice in the G1, G2, and G3 groups was collected to detect the concentration of protein markers of OSCC. Also, venous blood and cancer tissues of mice in the three groups were collected for drug concentration measurements. The paclitaxel concentration and retention in G3 mice were significantly higher and more prolonged than those in G2 mice, respectively (P < 0.05). Compared to the level of OSCC protein markers in the saliva of mice in G1 and G2 that in G3 was the lowest. PTX-mPEG-PLA NPs demonstrates effective targeting in the treatment of oral squamous cell carcinoma in mice. It can deliver the drug to the cancerous tissues, increase the drug retention in the same tissues, and effectively inhibit the proliferation and metastasis of malignant tumors.


2021 ◽  
Vol 11 (8) ◽  
pp. 1299-1305
Author(s):  
Xiangyong Cheng ◽  
Lan Zhang ◽  
Xiqing Liu ◽  
Liangpeng Xu ◽  
Junjie Liu

Cisplatin, a non-specific cell cycle antineoplastic drug, has therapeutic effects on a variety of malignant tumors. However, cisplatin has some drawbacks, such as poor targeting, which can lead to damage in normal tissue adjacent to a cancer, causing serious side effects in patients. In this study, we designed and developed a folic acid (FA)-mediated cisplatin magnetic nanodrug, FA-CDDP-MNPs, and investigated its efficacy in the treatment of oral squamous cell carcinoma (OSCC). In vitro and in vivo experiments showed that FA-CDDP-MNPs had a greater inhibitory effect on OSCC than CDDP alone. Due to the introduction of FA, the targeting of FA-CDDPMNPs was improved, and its cytotoxicity reduced. The successful design and development of FA-CDDP-MNPs provides a basis for novel drug development and design in the future.


2021 ◽  
Vol 17 (6) ◽  
pp. 1098-1108
Author(s):  
Ziyu Zhu ◽  
Jiaxing Gong ◽  
Jianlu Kong ◽  
Ying Qian ◽  
Kejie Lu ◽  
...  

Oral squamous cell carcinoma (OSCC) is one of the most common tumors worldwide and has one of the highest mortalities. The progression of OSCC is accompanied by changes in the levels of many genes. Iroquois homeobox 5 (IRX5), a novel protein involved in several embryonic developmental processes, has been found in recent years to play a significant role in regulating the growth of malignant tumors. However, its role and mechanism in OSCC are still unclear. In this study, we used nano-PCR to examine the levels of IRX5 in OSCC tissues. Through overexpression and knockdown experiments, we researched the role of IRX5 in regulating OSCC cell multiplication, metastasis, and epithelial-mesenchymal transition (EMT). The results demonstrated that IRX5 expression is higher in OSCC tissues in contrast to adjacent tissues. Overexpression of IRX5 promotes the multiplication, metastasis, invasion, and EMT of OSCC cells. Additional bioinformatics analysis showed that miRNA-147 can target the 3’UTR end of IRX5 and negatively regulate its expression, and overexpression of miRNA-147 can weaken the cancer-promoting effect of IRX5. In conclusion, this study found that IRX5 plays a role in promoting cancer in OSCC, and IRX5 is also negatively regulated by miRNA-147.


2021 ◽  
Vol 11 ◽  
Author(s):  
Yali Cheng ◽  
Shaoming Li ◽  
Ling Gao ◽  
Keqian Zhi ◽  
Wenhao Ren

Oral squamous cell carcinoma (OSCC) is a kind of malignant tumors with low survival rate and prone to have early metastasis and recurrence. Cisplatin is an alkylating agent which induces DNA damage through the formation of cisplatin-DNA adducts, leading to cell cycle arrest and apoptosis. In the management of advanced OSCC, cisplatin-based chemotherapy or chemoradiotherapy has been considered as the first-line treatment. Unfortunately, only a portion of OSCC patients can benefit from cisplatin treatment, both inherent resistance and acquired resistance greatly limit the efficacy of cisplatin and even cause treatment failure. Herein, this review outline the underlying mechanisms of cisplatin resistance in OSCC from the aspects of DNA damage and repair, epigenetic regulation, transport processes, programmed cell death and tumor microenvironment. In addition, this review summarizes the strategies applicable to overcome cisplatin resistance, which can provide new ideas to improve the clinical therapeutic outcome of OSCC.


Sign in / Sign up

Export Citation Format

Share Document